	4 (JNIT	ED STA	TES	SE	CURITI	ES A	ND	ЕХСНА	NGE	сом	MIS	SION				
				Washington, D.C. 20549											OMB APPROVAL		
Section 16. Form 4 or Form 5 obligations may continue. See											RSH	IIP	Estim	ated average bur	3235-028 den 0.3		
1. Name and Address of Reporting Person [*] Welgus Howard G.				2.1	2. Issuer Name and Ticker or Trading Symbol Arcutis Biotherapeutics, Inc. [ARQT]						(Check	k all applie	cable)	0 ()	ssuer Owner		
CUTIS BIO	UTIS BIOTHERAPEUTICS, IN				3. Date of Earliest Transaction (Month/Day/Year) 09/01/2020								Officer below)	(give title		(specify /)	
Street) WESTLAKE CA 91361 VILLAGE					4. If Amendment, Date of Original Filed (Month/Day/Year) 09/02/2020												
(S	tate)	(Zip)															
	Tab	le I - N	Non-Deriv	ative	e Sec	urities A	cquire	əd, C)isposed (of, or E	Benefic	ally	Owned	l			
1. Title of Security (Instr. 3)			Date		ear) if any		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4 a		d (A) or r. 3, 4 and	l 5)	Securiti Benefic Owned	es ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
							Code	v	Amount	(A) or (D)	Price		Transac	tion(s)		(1130.4)	
Common Stock			09/01/2020)		M ⁽¹⁾		1,028	Α	\$1.	68	177	7,206	D		
Common Stock			09/01/2020)		S ⁽¹⁾		1,028	D	\$24.3	833(2)	176	5,178	D		
Common Stock			09/01/2020)		M ⁽¹⁾		1,172	Α	\$1.	68	177	7,350	D		
Common Stock			09/01/2020				S ⁽¹⁾		1,172	D	\$24.3833 ⁽²⁾		176	5,178	D		
Common Stock													24	,991	Ι	By Trust ⁽³⁾	
	T	able I											wned				
2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execut if any	tion Date,	Transa Code (5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	Expira	ation D	ate	Amoun Securiti Underly Derivati	t of ies ring ive Secur	De Se (Ir	erivative ecurity	derivative Securities Beneficia Owned Following Reported	e Ownersh Form: Ily Direct (D or Indire (I) (Instr.	Benefic) Owners ct (Instr. 4	
	x this box if no lo no 16. Form 4 or titions may contii cition 1(b). and Address of <u>s Howard</u> (Fi CUTIS BIO DWNSGATH AKE GE (S Security (Inst n Stock n Stock n Stock n Stock n Stock n Stock n Stock	FORM 4	FORM 4 UNIT Athis box if no longer subject to on 16. Form 4 or Form 5 itions may continue. See cition 1(b). ST and Address of Reporting Person*	FORM 4 UNITED STATEMENT kthis box if no longer subject to nn 16. Form 4 or Form 5 titons may continue. See cition 1(b). STATEMENT ind Address of Reporting Person* s Howard G. File ind Address of Reporting Person* s Howard G. (Middle) CUTIS BIOTHERAPEUTICS, INC. OWNSGATE ROAD, SUITE 110 AKE GE CA 91361 (State) (Zip) Table I - Non-Deriv Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 1 Stock 09/01/20 n Stock 09/01/20 0 Stock 0	FORM 4 UNITED STATES It is box if no longer subject to an 16. Form 4 or Form 5 titons may continue. See cition 1(b). STATEMENT (and the purs or	FORM 4 UNITED STATES SET At this box if no longer subject to no n 16, Form 4 or Form 5 titons may continue. See cition 1(b). STATEMENT OF 02 Title pursuant to or Section Ind Address of Reporting Person* S Howard G. ?. Issuer N Arcuitis (First) (Middle) CUTIS BIOTHERAPEUTICS, INC. 09/01/202 OWNSGATE ROAD, SUITE 110 4. If Amen 09/02/20 AKE GE CA 91361 (State) (Zip) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. A. D. Execution 1 Stock 09/01/2020 1 1 1 Stock 09/01/2020 1	FORM 4 UNITED STATES SECURITI wash STATEMENT OF CHANG wash STATEMENT OF CHANG wash Filed pursuant to Section 160 or Section 30(h) of the or	FORM 4 UNITED STATES SECURITES A Washington. STATEMENT OF CHANGES II Store of rom 5 tions may continue. See cition 1(b). Filed pursuant to Section 16(a) of th or Section 30(h) of the Invest Index pursuant to Section 16(a) of th or Section 30(h) of the Invest Index pursuant to Section 16(a) of th or Section 30(h) of the Invest Index pursuant to Section 16(a) of th or Section 30(h) of the Invest Index pursuant to Section 16(a) of th or Section 30(h) of the Invest (First) (Middle) (First) (Middle) CUTITS BIOTHERAPEUTICS, INC. OWNSGATE ROAD, SUITE 110 A. Hermedment, Date of Orig 09/02/2020 Security (Instr. 3) 2. Transaction Date (Month/Day/Vear) A. Deemed Execution Date, Month/Day/Vear) 3. Transaction Date Security (Instr. 3) Security (Instr. 3) Conversion A. Stock 09/01/2020 Month Stock 09/01/2020 Security Stock 09/01/2020 Security Stock 09/01/2020 Security Stock <td>FORM 4 UNITED STATES SECURITIES AND Washington, D.C.4 Kthis box if no longer subject to into 16. Form 4 or Form 5 tions may continue. See citon 100. STATEMENT OF CHANGES IN BI Filed pursuant to Section 18(a) of the Sec or Section 30(h) of the Investment Arcutis Biotherapeutics, (First) Ind Address of Reporting Person's S Howard G. Filed pursuant to Section 18(a) of the Sec or Section 30(h) of the Investment Arcutis Biotherapeutics, (First) 2. Issuer Name and Ticker or Tradiu Arcutis Biotherapeutics, (MonthyDayYear) AKE GE CA 91361 3. Date of Earliest Transaction (Mor 09/01/2020 AKE GE CA 91361 3. Transaction Date (MonthyDayYear) 3. Transaction Code (Instr. 1 Stock 3. Transaction Code (Instr. 1 Stock 3. Transaction Code (Instr. 1 Stock 5. Number Securities Acquired, Dis (e.g., puts, calls, warrants, options 2 Table II - Derivative Securities Acquired, Dis (e.g., puts, calls, warrants, options 6. Date Exer Execution Date, If any (MonthyDay/Year) 5. Number Securities Acquired (A) or Disposed of (D)</td> <td>FORM 4 UNITED STATES SECURITIES AND EXCHANA Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFIC: This box if no longer subject to in 16, Form 4 or Form 5 This box if no longer subject to in 16, Form 4 or Form 5 This box if no longer subject to in 16, Form 4 or Form 5 This box if no longer subject to in 16, Form 4 or Form 5 This box if no longer subject to in 16, Form 4 or Form 5 Itied pursuant to Section 16(a) of the Securities Exchar osciton 30(h) of the Investment Company Act Address of Reporting Person* Statement Toker or Trading Symbol (First) (Middle) CUTIS BIOTHERAPEUTICS, INC. DWNSGATE ROAD, SUITE 110 A text of Earliest Transaction (Month/Day/Year) AKE OVI/2020 CA 91361 AKE OP/01/2020 State of Earliest Transaction To OP/01/2020 State of Carliest Transaction To Transaction To Transaction To Transaction To Transaction To To Stock Op/01/2020 State of Carliest Transaction To Transaction To To Stock Op/01/2020 A mount State Marchan Ma</td> <td>FORM 4 UNITED STATES SECURITES AND EXCHANGE Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL ON Intel form 4 or form 5 of the may or form 5 of the may or form 5 of section 30(h) of the lowestment change Act of or Section 30(h) of the Investment change Act of Op(1/2020 AKE Security (Instr. 3) 2. Transaction Date (State) 2. Transaction Date (Date Act Op(0)(1/2020 3. Answer (h) of the Investment change (h) of th</td> <td>FORM 4 UNITED STATES SECURITIES AND EXCHANGE COM Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNER In 16, Erm 4 or Firm 5 and or Section 30(h) of the Investment Company Act of 1940 or Section 30(h) of the Investment Company Act of 1940 or Section 30(h) of the Investment Company Act of 1940 or Section 30(h) of the Investment Company Act of 1940 or Section 30(h) of the Investment Company Act of 1940 address of Reporting Person* S Howard G, (First) 2. Issuer Name and Ticker or Trading Symbol Arcutis Biother apeutics, Inc. [ARQT] (First) (Middle) CUTIS BIOTHERAPEUTICS, INC. DWNSGATE ROAD, SUITE 110 3. Date of Earliest Transaction (Month/Day/Year) 09/01/2020 AKE GE CA 91361 (State) (Zip) 4. If Amendment, Date of Original Filed (Month/Day/Year) 09/02/2020 Table 1 - Non-Derivative Securities Acquired, Disposed of, OV Emergine (Month/Day/Year) 5. Securites (Month/Day/Year) 09/01/2020 5. Securites Acquired (A) or 100 (Instr. A) 1 Stock 09/01/2020 M⁽¹⁾ 1.028 A 1 Stock 09/01/2020 M⁽¹⁾ 1.172 A 1 Stock 09/01/2020 S⁽¹⁾ 1.172 A S1. 1 Stock 09/01/2020 S⁽¹⁾ 1.172 D S24.3</td> <td>FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMIS Washington, D. C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSH In 16, Form 4 or Form 5 torn 10). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1934 or Section 30(h) of the Investment C</td> <td>FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP in the form any continue. See clion 100. Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1934 A defense of Reporting Person' <u>S Howard G.</u> S. Relationship in Curits BioTHERAPEUTICS, INC. WNNSGATE ROAD, SUITE 110 A the of Driginal Filed (Month/Day/Year) 0.010/2020 S. Individual or Units: BioTHERAPEUTICS, INC. AKE CA 91361 0.100 (State) Calment of Driginal Filed (Month/Day/Year) 0.001/2020 S. Anomed Transaction 0.001/2020 S. Anomed Transaction 0.0001/2020 S. Anomed Transaction 0.0001/2020 S. Anomed Transaction 0.0001/2020 S. Anomed Transaction 0.0001/2020 S. Anomed Transaction 0.0001/10020/Year) S. Anomed Transaction 0.0001/2020 S. Anomed Transaction 0.0001/2020 S. Anomed Transaction 0.0001/2020 S. Anomed Transaction 0.00001/2020 <th colspa<="" td=""><td>FORM 4 UNITED STATES SECURITES AND EXCHANGE COMMISSION Washington, D.C. 2059 United parability in 15 form of orburg born my continue. See citon 16) STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Teled parsuant to Section 16(a) of the Securities Exchange Act of 1930 Ind Address of Reporting Person's SHoward G, (First) 2 issuer Name and Toker or Transaction (Month/Day/Year) 5. Relationship of Reporting 0.000 5. Relationship of Reporting 0.000 5. Relationship of Report 0.000 6. Individual or Joint/Gou Not Person AKE 3B CA 91361 3. Date of Earliest Transaction (Month/Day/Year) 6. Individual or Joint/Gou Not Person 7. Transaction Report 0.000 7. Transaction 1.0000 7. Transaction 1.0000 7. Transaction 1.0000 7. Transaction 1.0000 7. Transaction 1.0000 8. Appender 1.0000 8. Appender 1.00000 8. Appender 1.00000 8. Appender 1.00000 8. Appender 1.00000 8. Appender 1.00000 8. Appender 1.00000 8. Appender 1.0</td><td>FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.2. 2059 State of a room of the form of orgen subjects to boom on ontinue. See on the norm of orgen subjects to boom on ontinue. See on the form of orgen subjects to boom on ontinue. See on the control ontinue. See on the controom the control ontinue. See on the control ontinu</td></th></td>	FORM 4 UNITED STATES SECURITIES AND Washington, D.C.4 Kthis box if no longer subject to into 16. Form 4 or Form 5 tions may continue. See citon 100. STATEMENT OF CHANGES IN BI Filed pursuant to Section 18(a) of the Sec or Section 30(h) of the Investment Arcutis Biotherapeutics, (First) Ind Address of Reporting Person's S Howard G. Filed pursuant to Section 18(a) of the Sec or Section 30(h) of the Investment Arcutis Biotherapeutics, (First) 2. Issuer Name and Ticker or Tradiu Arcutis Biotherapeutics, (MonthyDayYear) AKE GE CA 91361 3. Date of Earliest Transaction (Mor 09/01/2020 AKE GE CA 91361 3. Transaction Date (MonthyDayYear) 3. Transaction Code (Instr. 1 Stock 3. Transaction Code (Instr. 1 Stock 3. Transaction Code (Instr. 1 Stock 5. Number Securities Acquired, Dis (e.g., puts, calls, warrants, options 2 Table II - Derivative Securities Acquired, Dis (e.g., puts, calls, warrants, options 6. Date Exer Execution Date, If any (MonthyDay/Year) 5. Number Securities Acquired (A) or Disposed of (D)	FORM 4 UNITED STATES SECURITIES AND EXCHANA Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFIC: This box if no longer subject to in 16, Form 4 or Form 5 This box if no longer subject to in 16, Form 4 or Form 5 This box if no longer subject to in 16, Form 4 or Form 5 This box if no longer subject to in 16, Form 4 or Form 5 This box if no longer subject to in 16, Form 4 or Form 5 Itied pursuant to Section 16(a) of the Securities Exchar osciton 30(h) of the Investment Company Act Address of Reporting Person* Statement Toker or Trading Symbol (First) (Middle) CUTIS BIOTHERAPEUTICS, INC. DWNSGATE ROAD, SUITE 110 A text of Earliest Transaction (Month/Day/Year) AKE OVI/2020 CA 91361 AKE OP/01/2020 State of Earliest Transaction To OP/01/2020 State of Carliest Transaction To Transaction To Transaction To Transaction To Transaction To To Stock Op/01/2020 State of Carliest Transaction To Transaction To To Stock Op/01/2020 A mount State Marchan Ma	FORM 4 UNITED STATES SECURITES AND EXCHANGE Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL ON Intel form 4 or form 5 of the may or form 5 of the may or form 5 of section 30(h) of the lowestment change Act of or Section 30(h) of the Investment change Act of Op(1/2020 AKE Security (Instr. 3) 2. Transaction Date (State) 2. Transaction Date (Date Act Op(0)(1/2020 3. Answer (h) of the Investment change (h) of th	FORM 4 UNITED STATES SECURITIES AND EXCHANGE COM Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNER In 16, Erm 4 or Firm 5 and or Section 30(h) of the Investment Company Act of 1940 or Section 30(h) of the Investment Company Act of 1940 or Section 30(h) of the Investment Company Act of 1940 or Section 30(h) of the Investment Company Act of 1940 or Section 30(h) of the Investment Company Act of 1940 address of Reporting Person* S Howard G, (First) 2. Issuer Name and Ticker or Trading Symbol Arcutis Biother apeutics, Inc. [ARQT] (First) (Middle) CUTIS BIOTHERAPEUTICS, INC. DWNSGATE ROAD, SUITE 110 3. Date of Earliest Transaction (Month/Day/Year) 09/01/2020 AKE GE CA 91361 (State) (Zip) 4. If Amendment, Date of Original Filed (Month/Day/Year) 09/02/2020 Table 1 - Non-Derivative Securities Acquired, Disposed of, OV Emergine (Month/Day/Year) 5. Securites (Month/Day/Year) 09/01/2020 5. Securites Acquired (A) or 100 (Instr. A) 1 Stock 09/01/2020 M ⁽¹⁾ 1.028 A 1 Stock 09/01/2020 M ⁽¹⁾ 1.172 A 1 Stock 09/01/2020 S ⁽¹⁾ 1.172 A S1. 1 Stock 09/01/2020 S ⁽¹⁾ 1.172 D S24.3	FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMIS Washington, D. C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSH In 16, Form 4 or Form 5 torn 10). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1934 or Section 30(h) of the Investment C	FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP in the form any continue. See clion 100. Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1934 A defense of Reporting Person' <u>S Howard G.</u> S. Relationship in Curits BioTHERAPEUTICS, INC. WNNSGATE ROAD, SUITE 110 A the of Driginal Filed (Month/Day/Year) 0.010/2020 S. Individual or Units: BioTHERAPEUTICS, INC. AKE CA 91361 0.100 (State) Calment of Driginal Filed (Month/Day/Year) 0.001/2020 S. Anomed Transaction 0.001/2020 S. Anomed Transaction 0.0001/2020 S. Anomed Transaction 0.0001/2020 S. Anomed Transaction 0.0001/2020 S. Anomed Transaction 0.0001/2020 S. Anomed Transaction 0.0001/10020/Year) S. Anomed Transaction 0.0001/2020 S. Anomed Transaction 0.0001/2020 S. Anomed Transaction 0.0001/2020 S. Anomed Transaction 0.00001/2020 <th colspa<="" td=""><td>FORM 4 UNITED STATES SECURITES AND EXCHANGE COMMISSION Washington, D.C. 2059 United parability in 15 form of orburg born my continue. See citon 16) STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Teled parsuant to Section 16(a) of the Securities Exchange Act of 1930 Ind Address of Reporting Person's SHoward G, (First) 2 issuer Name and Toker or Transaction (Month/Day/Year) 5. Relationship of Reporting 0.000 5. Relationship of Reporting 0.000 5. Relationship of Report 0.000 6. Individual or Joint/Gou Not Person AKE 3B CA 91361 3. Date of Earliest Transaction (Month/Day/Year) 6. Individual or Joint/Gou Not Person 7. Transaction Report 0.000 7. Transaction 1.0000 7. Transaction 1.0000 7. Transaction 1.0000 7. Transaction 1.0000 7. Transaction 1.0000 8. Appender 1.0000 8. Appender 1.00000 8. Appender 1.00000 8. Appender 1.00000 8. Appender 1.00000 8. Appender 1.00000 8. Appender 1.00000 8. Appender 1.0</td><td>FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.2. 2059 State of a room of the form of orgen subjects to boom on ontinue. See on the norm of orgen subjects to boom on ontinue. See on the form of orgen subjects to boom on ontinue. See on the control ontinue. See on the controom the control ontinue. See on the control ontinu</td></th>	<td>FORM 4 UNITED STATES SECURITES AND EXCHANGE COMMISSION Washington, D.C. 2059 United parability in 15 form of orburg born my continue. See citon 16) STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Teled parsuant to Section 16(a) of the Securities Exchange Act of 1930 Ind Address of Reporting Person's SHoward G, (First) 2 issuer Name and Toker or Transaction (Month/Day/Year) 5. Relationship of Reporting 0.000 5. Relationship of Reporting 0.000 5. Relationship of Report 0.000 6. Individual or Joint/Gou Not Person AKE 3B CA 91361 3. Date of Earliest Transaction (Month/Day/Year) 6. Individual or Joint/Gou Not Person 7. Transaction Report 0.000 7. Transaction 1.0000 7. Transaction 1.0000 7. Transaction 1.0000 7. Transaction 1.0000 7. Transaction 1.0000 8. Appender 1.0000 8. Appender 1.00000 8. Appender 1.00000 8. Appender 1.00000 8. Appender 1.00000 8. Appender 1.00000 8. Appender 1.00000 8. Appender 1.0</td> <td>FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.2. 2059 State of a room of the form of orgen subjects to boom on ontinue. See on the norm of orgen subjects to boom on ontinue. See on the form of orgen subjects to boom on ontinue. See on the control ontinue. See on the controom the control ontinue. See on the control ontinu</td>	FORM 4 UNITED STATES SECURITES AND EXCHANGE COMMISSION Washington, D.C. 2059 United parability in 15 form of orburg born my continue. See citon 16) STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Teled parsuant to Section 16(a) of the Securities Exchange Act of 1930 Ind Address of Reporting Person's SHoward G, (First) 2 issuer Name and Toker or Transaction (Month/Day/Year) 5. Relationship of Reporting 0.000 5. Relationship of Reporting 0.000 5. Relationship of Report 0.000 6. Individual or Joint/Gou Not Person AKE 3B CA 91361 3. Date of Earliest Transaction (Month/Day/Year) 6. Individual or Joint/Gou Not Person 7. Transaction Report 0.000 7. Transaction 1.0000 7. Transaction 1.0000 7. Transaction 1.0000 7. Transaction 1.0000 7. Transaction 1.0000 8. Appender 1.0000 8. Appender 1.00000 8. Appender 1.00000 8. Appender 1.00000 8. Appender 1.00000 8. Appender 1.00000 8. Appender 1.00000 8. Appender 1.0	FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.2. 2059 State of a room of the form of orgen subjects to boom on ontinue. See on the norm of orgen subjects to boom on ontinue. See on the form of orgen subjects to boom on ontinue. See on the control ontinue. See on the controom the control ontinue. See on the control ontinu

Explanation of Responses:

\$1.68

\$1 68

1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

09/01/2020

09/01/2020

2. The transaction was executed in multiple trades in prices ranging from \$24.00 to \$25.00, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Date

Exercisable

(4)

(4)

(A) (D)

1,028

1,172

Code V

M⁽¹⁾

M⁽¹⁾

Expiration

03/13/2029

03/13/2029

Date

Title

Common

Stock

Common Stock

3. The securities are held of record by The Welgus Living Trust, of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes

4. The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.

Remarks:

Stock Option

(Right to Buy)

Stock Option (Right to

Buy)

Amendment made to number of shares beneficially owned in Table II.

<u>/s/ John W. Smither, as</u> <u>Attorney-in-Fact for Howard</u> <u>10/05/2020</u> <u>G. Welgus</u>

or Number

Shares

1,028

1,172

\$0.00

\$0.00

36,391

14,838

D

D

of

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.